Pharming Group Nv Stock Buy Hold or Sell Recommendation
| PHAR Stock | USD 7.53 0.23 2.96% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Pharming Group NV is 'Not Rated'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Pharming Group NV given historical horizon and risk tolerance towards Pharming Group. When Macroaxis issues a 'buy' or 'sell' recommendation for Pharming Group NV, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Pharming Group Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Pharming and provide practical buy, sell, or hold advice based on investors' constraints. Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Pharming |
Execute Pharming Group Buy or Sell Advice
The Pharming recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Pharming Group NV. Macroaxis does not own or have any residual interests in Pharming Group NV or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Pharming Group's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Pharming Group Trading Alerts and Improvement Suggestions
| Pharming Group NV generated a negative expected return over the last 90 days | |
| Pharming Group NV has high historical volatility and very poor performance | |
| Pharming Group NV has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 245.32 M. Net Loss for the year was (9.55 M) with profit before overhead, payroll, taxes, and interest of 188.06 M. | |
| Pharming Group NV currently holds about 189.96 M in cash with (17.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91. | |
| Latest headline from finance.yahoo.com: Pharming Group to participate in November investor conference |
Pharming Group Returns Distribution Density
The distribution of Pharming Group's historical returns is an attempt to chart the uncertainty of Pharming Group's future price movements. The chart of the probability distribution of Pharming Group daily returns describes the distribution of returns around its average expected value. We use Pharming Group NV price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Pharming Group returns is essential to provide solid investment advice for Pharming Group.
| Mean Return | -0.02 | Value At Risk | -5.6 | Potential Upside | 5.19 | Standard Deviation | 3.34 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Pharming Group historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Pharming Stock Institutional Investors
The Pharming Group's institutional investors refer to entities that pool money to purchase Pharming Group's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Silverberg Bernstein Capital Management Llc | 2024-09-30 | 41.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.6 K | Ubs Group Ag | 2024-06-30 | 789 | Advisor Group Holdings, Inc. | 2024-06-30 | 568 |
Pharming Group Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 3.4M | (3.4M) | (5.9M) | (15.0M) | (14.4M) | (13.7M) | |
| Change In Cash | (14.5M) | 123.9M | 2.6M | 15.4M | (145.6M) | (138.3M) | |
| Free Cash Flow | 49.1M | 74.5M | 20.2M | 20.9M | (18.8M) | (17.8M) | |
| Depreciation | 5.8M | 8.9M | 18.7M | 13.2M | 15.9M | 16.7M | |
| Other Non Cash Items | (3.1M) | 33.3M | (7.8M) | (11.3M) | (16.0M) | (15.2M) | |
| Capital Expenditures | 25.4M | 16.5M | 16.0M | 2.0M | 1.5M | 1.4M | |
| Net Income | 68.2M | 47.5M | 22.0M | 15.0M | (9.6M) | (9.1M) | |
| End Period Cash Flow | 76.8M | 205.5M | 191.7M | 207.3M | 61.7M | 72.2M | |
| Net Borrowings | (33.4M) | 73.0M | (2.8M) | (3.3M) | (3.8M) | (3.6M) | |
| Change To Netincome | 25.1M | 36.3M | 6.1M | (3.6M) | (3.2M) | (3.1M) |
Pharming Group Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Pharming Group or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Pharming Group's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Pharming stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.0007 | |
β | Beta against Dow Jones | -0.36 | |
σ | Overall volatility | 3.31 | |
Ir | Information ratio | -0.04 |
Pharming Group Volatility Alert
Pharming Group NV exhibits very low volatility with skewness of -0.16 and kurtosis of -0.44. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pharming Group's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pharming Group's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Pharming Group Fundamentals Vs Peers
Comparing Pharming Group's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pharming Group's direct or indirect competition across all of the common fundamentals between Pharming Group and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pharming Group or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Pharming Group's fundamental indicators could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Pharming Group to competition |
| Fundamentals | Pharming Group | Peer Average |
| Return On Equity | -0.0818 | -0.31 |
| Return On Asset | -0.0138 | -0.14 |
| Profit Margin | (0.06) % | (1.27) % |
| Operating Margin | 0.05 % | (5.51) % |
| Current Valuation | 457.15 M | 16.62 B |
| Shares Outstanding | 67.84 M | 571.82 M |
| Shares Owned By Institutions | 0.10 % | 39.21 % |
| Number Of Shares Shorted | 9.62 K | 4.71 M |
| Price To Earning | 41.53 X | 28.72 X |
| Price To Book | 2.33 X | 9.51 X |
| Price To Sales | 1.84 X | 11.42 X |
| Revenue | 245.32 M | 9.43 B |
| Gross Profit | 188.06 M | 27.38 B |
| EBITDA | 9.88 M | 3.9 B |
| Net Income | (9.55 M) | 570.98 M |
| Cash And Equivalents | 189.96 M | 2.7 B |
| Cash Per Share | 2.91 X | 5.01 X |
| Total Debt | 171.54 M | 5.32 B |
| Debt To Equity | 0.75 % | 48.70 % |
| Current Ratio | 5.22 X | 2.16 X |
| Book Value Per Share | 0.44 X | 1.93 K |
| Cash Flow From Operations | (17.3 M) | 971.22 M |
| Short Ratio | 1.32 X | 4.00 X |
| Earnings Per Share | (0.27) X | 3.12 X |
| Target Price | 33.5 | |
| Number Of Employees | 382 | 18.84 K |
| Beta | 0.81 | -0.15 |
| Market Capitalization | 526.4 M | 19.03 B |
| Total Asset | 462.85 M | 29.47 B |
| Retained Earnings | (265.26 M) | 9.33 B |
| Working Capital | 238.37 M | 1.48 B |
| Net Asset | 462.85 M |
Note: Acquisition by Camden Partners Strategic Fund Ii A Lp of 5000 shares of Pharming Group at 0.68 subject to Rule 16b-3 [view details]
Pharming Group Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Pharming . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Pharming Group Buy or Sell Advice
When is the right time to buy or sell Pharming Group NV? Buying financial instruments such as Pharming Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Pharming Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ESG Investing Thematic Idea Now
ESG Investing
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.